medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2012, Number 2

<< Back Next >>

Rev Invest Clin 2012; 64 (2)

Experimental bacterial contamination of bile and liver in mongrel dogs: an alternative treatment with cephalone, a hybrid of cephalosporine fluoroquinolone

Carmona-Mancilla A, Villegas-Álvarez F, Sumano-López H, Ocampo-Camberos L, Pérez-Guille BE, González ZJF, Coria-Jiménez R, Soriano-Rosales RE, Jiménez-Bravo-Luna MÁ, González-Maciel A

Language: Spanish
References: 28
Page: 173-181
PDF size: 237.46 Kb.


ABSTRACT

Objectives. A longitudinal, randomized, single blind study was done to evaluate the efficacy of an antibacterial hybrid molecule (β-lactamic-fluoroquinolone) named cephalone after biliary-enteric-bypass (BEB). Material and methods. Four groups of mongrel dogs were operated on three consecutive periods. Cultures of bile and liver were obtained and assessed, followed by obliteration of common bile duct and BEB to groups A, B and C. Group D served as a control. Ten days later the group A received conventional treatment based on ampicillin/gentamicin and groups B and C, cephalone in two different concentration schemes during 10 consecutive days. Further samples were processed for bacteria and additional liver biopsies were obtained for histopathological analysis. Results. All three treatments reverted bacterial contamination in the liver and most of the bile samples were negative or showed a significant decrease in the number of colony forming units (p = 0.002). Histopathological analysis proved no lesions. Conclusions. Comparison of efficacy among antibacterial treatments revealed undistinguishable efficacy in this short-term assessment of bacterial contamination after BEB in dogs. The use of cephalone could be considered as a viable treatment or prophylaxis in bacterial infections occurring after BEB. Further studies are needed to assess longterm impact of the cephalone in this setting.


REFERENCES

  1. Kasai M. Treatment of biliary atresia with special reference to hepatic portoenterostomy and its modifications. Prog Pediatr Surg 1974; 6: 5-51.

  2. Sanghai SR, Shah I, Bhatnagar S, Murthy A. Incidence and prognostic factors associated with biliary atresia in western India. Ann Hepatol 2009; 8: 120-2.

  3. Shinkai M, Ohhama Y, Take H, Kitagawa N, Kudo H, Mochizuki K, Hatata T. Long-term outcome of children with biliary atresia who were not transplants after the Kasai operation: > 20-year experience at a children’s hospital. J Pediatr Gastroenterol Nutr 2009; 48: 443-50.

  4. Stringer MD, Davison SM, Rajwal SR, McClean P. Kasai portoenterostomy: 12-year experience with a novel adjuvant therapy regimen. J Pediatr Surg 2007; 42: 1324-8.

  5. Paterson DL. Resistance in gram-negative bacteria: enterobacteriacea. Am J Med 2006; 119(6, Supl. 1): S20-S28.

  6. Nordmann P. Gram-negative bacteriae with resistance to carbapenems. Med Sci 2010; 26(11): 950-9.

  7. Page MGP, Heim J. Prospects for the next anti-pseudomonas drug. Curr Opin Pharmacol 2009; 9: 558-65.

  8. Santamaría JA. Eficacia clínica de un preparado intramamario a base de una cefaquinolona experimental (CQEPCA-600M) para el tratamiento de la mastitis bovina. Tesis de licenciatura. Facultad de Medicina Veterinaria y Zootécnica. México: UNAM; 1997, p. 10-32.

  9. Villegas AF, Hernández GR, Candonosa AE, Ávila RE, Cravioto MJ. Derivación bilioentérica convergente con mecanismo antirreflujo. Estudio experimental. Bol Med Hosp Infant Mex 1990; 47: 342-8.

  10. Versalovic J, Carrol KC, Funken G, Jorgensen JH, Lanfry ML, Warnock DW (eds.). Manual of Clinical Microbiology. 10th. Ed. Washington, USA: ASM Press; 2011.

  11. Asia RM. The Box-Cox transformation technique: a review. The Statistician 1992; 41; 169-78.

  12. Wong KKY, Fan AH, Lan LCL, Lin SCL, Tam PKH. Effective antibiotic regime for postoperative acute cholangitis in biliary atresia-an evolving scene. J Pediatr Surg 2004; 39: 1800-002.

  13. Houben C, Phelan S, Davenport M. Late-presenting cholangitis and Roux loop obstruction after Kasai portoenterostomiy for biliary atresia. J Pediatr Sur 2006; 41: 1159-64.

  14. Sookpotarom P, Vejchapipat P, Chittmittrapap S, Chongsrisawat V, Chandrakamol B, Poovorawan Y. Short-term results of Kasai operation for biliary atresia: Experience from one institution. Asian J Surg 2006; 29: 188-92.

  15. Hussein A, Wyatt J, Guthrie A, Stringer MD. Kasai portoenterostomy- new insights from hepatic morphology. J Pediatr Surg 2005; 40: 322-6.

  16. Muraji T, Tsugawa C, Nishujima E, Satoh S, Takamizawa S, Ise K, Maekawa T. Surgical management for intractable cholangitis in biliary atresia. J Pediatr Surg 2002; 37: 1713-5.

  17. Nio M, Ohi R, Miyano T, Saeki M, Shiraki K, Tanaka K. Fiveand 10-year survival rates after surgery for biliary atresia: A report from the Japanese Biliary Atresia Registry. J Pediatr Surg 2003; 38: 997-1000.

  18. Ogasawara Y, Yamataka A, Tsukamoto K, Okada Y, Lane GJ, Kobayashi H, Miyano T. The intussusceptions antireflux valve is ineffective for preventing cholangitis in biliary atresia: a prospective study. J Pediatr Surg 2003; 38: 1826-29.

  19. Bowles BJ, Bdul-Ghani A, Zhang JZ, Shim WKT. Fifteen years experience with antirefluxing biliary drainage valve. J Pediatr Surg 1999; 34: 1711-4.

  20. Kobayashi H, Yamakata A, Koga H, Okazaki T, Tamura T, Urao M et al. Optimum prednisolone usage in patients with biliary atresia postportoenterostomy. J Pediatr Surg 2005; 40: 327-30.

  21. Dillon PW, Owings E, Cilley R, Field D, Curnow A, Georgeson K. Immunosuppresion as adjuvant therapy for biliary atresia. J Pediatr Surg 2001; 36: 80-5.

  22. Chiang J-H, Lee S-Y, Chen W-J, Hsieh C-S, Chang NN-K, Lo S-K. Changes in bacterial concentration in the liver correlate with that in the hepaticojejunostomy after bile duct reconstruction: Implication in the pathogenesis of postoperative cholangitis. Word J Surg 2001; 25: 1512-8.

  23. Rice LB. The clinical consequences of antimicrobial resistance. Curr Opin Microbiol 2009; 12: 476-81.

  24. Sumano LH, Ocampo CL, Azuara J. Clinical efficacy of cephalone- 1 (a new cefalosporin-fluoroquinolone antibacterial) in dogs with various respiratory bacterial infections. J Anim Vet Adv 2003; 2: 675-80.

  25. Sumano LH, Ocampo CL, Azuara J. Clinical efficacy of a cephalone (a new cephalosporin-fluoroquinolone antibacterial) in dogs with various respiratory bacterial infections. Abstract en: Second International Conference on Antimicrobial Agents in Veterinary Medicine (AAVM). Ottawa, Canada, June 13-17, 2004.

  26. Ovalle AI, Sumano H. Farmacocinética de la cefaquinolona (CQEPCA) en perros. Tesis de Licenciatura. Facultad de Medicina Veterinaria y Zootécnica. México: UNAM; 1996.

  27. Pérez GB, Sumano LH, Villegas AF, Soriano RR, González ZF, Jiménez BL, et al. Pharmacokinetics of cephalone (CQ-MEPCA) in rats after oral, intraduodenal and intravenous administration. Int J of Pharm 2004; 282: 87-94.

  28. Sumano LH, Ocampo CL, Mateos TG. Pharmacokinetics, tolerance and clinical efficacy of a new antibacterial CQ-M-EPCA for the treatment of respiratory diseases in dogs affected with various respiratory bacterial infections. Isr J Vet Med 1998; 53: 64-8.




2020     |     www.medigraphic.com